| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44024781 | HTLV-1 | ENSG00000119772.19 | protein_coding | DNMT3A | No | Yes | 1788 | A0A0C4DG02 F8WE91 Q9Y6K1 |
| TVIS44021967 | HTLV-1 | ENSG00000119772.19 | protein_coding | DNMT3A | No | Yes | 1788 | A0A0C4DG02 F8WE91 Q9Y6K1 |
| TVIS44018855 | HTLV-1 | ENSG00000119772.19 | protein_coding | DNMT3A | No | Yes | 1788 | A0A0C4DG02 F8WE91 Q9Y6K1 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DNMT3A |
|---|---|
| DrugBank ID | DB01262 |
| Drug Name | Decitabine |
| Target ID | BE0009880 |
| UniProt ID | Q9Y6K1 |
| Regulation Type | inhibitor |
| PubMed IDs | 17023173; 29455551; 27330573 |
| Citations | Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4.@@Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM: Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression. Drug Metab Rev. 2018 May;50(2):193-207. doi: 10.1080/03602532.2018.1437446. Epub 2018 Feb 18.@@Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS: A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016 Jun 21;8:71. doi: 10.1186/s13148-016-0237-y. eCollection 2016. |
| Groups | Approved; Investigational |
| Direct Classification | Triazinones |
| SMILES | NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1 |
| Pathways | |
| PharmGKB | PA164749631 |
| ChEMBL | CHEMBL1201129 |
